Protein binding in a congeneric series of antibacterial quinolone derivatives was written by Zlotos, Gabriele;Bucker, Annegret;Jurgens, Jens;Holzgrabe, Ulrike. And the article was included in International Journal of Pharmaceutics in 1998.HPLC of Formula: 21867-64-1 This article mentions the following:
The extent of plasma protein binding was determined in a series of gyrase inhibitors characterized either by a varying substitution on the Ph ring in position N-1 or by an increasing alkyl chain at the N-4′ of the piperazine moiety. An attempt was made to derive QSARs. Especially substituents at the m-position of the N-1-Ph ring influenced the extent of protein binding; an optimum of size was determined The increase of the alkyl group at the outer piperazine nitrogen which is combined with an augmented lipophilicity resulted in an increase in the degree of protein binding. So it can be concluded that the N-1-Ph ring as well as the piperazine ring take part in the interaction with the plasma protein. Both substituents can be used to regulate the extent of protein binding in new gyrase inhibitors. In the experiment, the researchers used many compounds, for example, 1-Propylpiperazine (cas: 21867-64-1HPLC of Formula: 21867-64-1).
1-Propylpiperazine (cas: 21867-64-1) belongs to piperazine derivatives. Piperazine belongs to the family of medicines called anthelmintics. Piperazine and its salts did not induce point mutations in a bacterial test. A series of mutagenicity studies in cells, both in vitro and in vivo, has been completed and showed no evidence of mutagenic effect.HPLC of Formula: 21867-64-1
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics